IE
CLDX icon

Israel Englander’s Celldex Therapeutics CLDX Stock Holding History

Israel Englander’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,400
Closed -$727K – 6011
2024
Q3 		$727K Buy
+21,400
New +$815K ﹤0.01% 4530
2022
Q3 		– Sell
-116,200
Closed -$3.13M – 7103
2022
Q2 		$3.13M Buy
+116,200
New +$3.37M ﹤0.01% 3249
2014
Q1 		– Sell
-2,333
Closed -$847K – 3486
2013
Q4 		$847K Buy
+2,333
New +$899K ﹤0.01% 2382

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's CLDX Position: Q2 2026 in Review

Israel Englander reduced its Celldex Therapeutics (CLDX) stake by 6.6% in Q2 2026, selling an estimated $2.67M and leaving 1,170,787 shares worth $43.6M. The position accounts for 0.02% of the portfolio, ranked #984.

Israel Englander first reported a position in CLDX in Q2 2013 and has held it in 42 quarters since. The position peaked at $57.7M in Q1 2015. 252 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Israel Englander held 1,170,787 shares of Celldex Therapeutics worth $43.6M as of Q2 2026.
  • Israel Englander sold 82,745 Celldex Therapeutics shares in Q2 2026, an estimated $2.67M.
  • Celldex Therapeutics made up 0.02% of Israel Englander's portfolio in Q2 2026, its #984 holding.
  • Israel Englander first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 42 quarters since.
  • Israel Englander's Celldex Therapeutics position peaked at $57.7M in Q1 2015.
  • 252 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.